Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Salarius Pharmaceuticals, LLC
Updated on 9 December 2021
ct scan
measurable disease
camptothecin
refractory ewing sarcoma
liposarcoma
myxoid liposarcoma

Summary

Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination of seclidemstat with topotecan and cyclophosphamide in patients with Ewing sarcoma

Description

The single agent expansion cohort of select sarcoma patients will enroll myxoid liposarcoma patients and patients with other sarcomas that share similar chromosomal translocations to Ewing sarcoma (FET-family translocations), including but not limited to desmoplastic small round cell tumor.

A safety lead-in dose escalation and dose expansion will be conducted assessing the combination of seclidemstat with topotecan and cyclophosphamide in patients with relapsed or refractory Ewing sarcoma.

Details
Condition Myxoid liposarcoma, Ewing's sarcoma, Myoepithelioma, Desmoplastic Small Round Cell Tumor, Clear cell sarcoma, Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor, Primary Pulmonary Myxoid Sarcoma
Treatment cyclophosphamide, Topotecan, SP-2577, Seclidemstat
Clinical Study IdentifierNCT03600649
SponsorSalarius Pharmaceuticals, LLC
Last Modified on9 December 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note